After years of delivering high-tech, high-cost treatments for cardiovascular disease, device companies are hard pressed to advance the cost-effective treatment arguments that drug companies have been touting in recent disease management programs. But in the cath lab, where price pressures are increasing, both ACS and SciMed are attempting a lateral entry into disease management through alliances with information systems companies.